Press "Enter" to skip to content

AFFiRiS GmbH alzheimers vaccine progress In the scientific phase I trial AFF001.

The treatment offers four vaccinations administered at regular intervals and is because of be fully finished by this October. The vaccine‘s tolerability can then become conclusively evaluated. Up to now the results indicate good tolerability for this Alzheimer’s vaccine from AFFiRiS GmbH. It really is on this basis that recruitment of further patients has already begun for the medical trial of a second Alzheimer’s vaccine by AFFiRiS. Vienna-based AFFiRiS GmbH has announced the successful completion of individual recruitment for clinical phase I testing of its Alzheimer’s vaccine AD01. The vaccine has been administered at the Vienna General Medical center to 24 Alzheimer’s sufferers at a moderate to moderate stage of the condition.Meanwhile, aside from those with seizures or upper respiratory tract infections, the use of MRI or ultrasound elevated. Usage of CT scans for seizures dropped by almost half, and 10 % fewer MRIs were used for kids having seizures. Children with serious head trauma also saw a big drop in CT scan use. Overall, the most typical reasons kids received CT scans included seizures, the task to drain excess liquid from the brain, removal of the appendix and brain surgery, a concussion or another head injury, the findings showed.